IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 228 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $74,616 | -37.5% | 16,400 | -3.3% | 0.00% | – |
| Q2 2023 | $119,480 | +16.0% | 16,962 | +0.6% | 0.00% | – |
| Q1 2023 | $102,980 | -3.8% | 16,859 | +0.0% | 0.00% | – |
| Q4 2022 | $107,000 | -50.0% | 16,856 | -24.5% | 0.00% | – |
| Q3 2022 | $214,000 | -12.7% | 22,340 | +0.5% | 0.00% | -100.0% |
| Q2 2022 | $245,000 | -36.9% | 22,230 | -4.5% | 0.00% | 0.0% |
| Q1 2022 | $388,000 | -16.2% | 23,279 | -4.0% | 0.00% | 0.0% |
| Q4 2021 | $463,000 | -26.3% | 24,256 | -4.9% | 0.00% | 0.0% |
| Q3 2021 | $628,000 | -4.7% | 25,514 | +0.8% | 0.00% | 0.0% |
| Q2 2021 | $659,000 | -15.4% | 25,312 | +2.9% | 0.00% | -50.0% |
| Q1 2021 | $779,000 | +46.2% | 24,595 | +114.2% | 0.00% | +100.0% |
| Q4 2020 | $533,000 | +40.3% | 11,480 | -1.8% | 0.00% | 0.0% |
| Q3 2020 | $380,000 | +21.0% | 11,686 | +2.2% | 0.00% | 0.0% |
| Q2 2020 | $314,000 | -5.4% | 11,437 | +3.0% | 0.00% | 0.0% |
| Q1 2020 | $332,000 | – | 11,104 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |